OCV Partners

The partnership is led by Managing Partner Hemi Zucker, who works alongside Co-Founder and Chairman Richard Ressler, and Partners Chris Bostick and Andy Liu. The four principals share investment-decision responsibilities, a structure that reflects the firm’s view that entrepreneurial experience matters more than a traditional hierarchical investment committee. All four have operator backgrounds — most notably Zucker and Ressler’s tenure scaling J2 Global.

OCV generates deal flow through a combination of its founders’ operating networks, particularly the contacts built during the growth of J2 Global, and its profile in the Los Angeles and Israeli startup ecosystems. The firm highlights its practice of initiating relationships with founders well before a fundraising process begins, a pattern noted by the CEO of Rad AI, who said OCV focused on building a relationship long before investing. Portfolio company Social Native credited Zucker’s M&A experience with enabling an acquisition during the COVID-19 pandemic.

OCV structures itself as a venture capital firm making direct investments in operating companies, not a fund-of-funds. The firm has not disclosed any allocation to external fund commitments, and its full portfolio list consists of direct equity stakes in startups across technology and healthcare. All capital is deployed directly into portfolio companies.

OCV invests from seed through late-stage venture and growth rounds. The firm describes itself as flexible capital, meaning it can lead rounds but does not require a lead position. Portfolio evidence includes early-stage bets such as Finch Therapeutics, which later went public, and later-stage infusions like Rad AI’s Series C round led by Khosla Ventures, demonstrating a willingness to follow top-tier syndicate leads.

OCV publicly states a dual focus on technology and healthcare, specifically naming SaaS, FinTech, PropTech, digital health, MedTech, and biotech as core sectors. There is no explicit exclusion list, but the firm’s stated expertise — rooted in software acquisitions, financial services, and healthcare operations — suggests it avoids heavy-industrial, hardware-intensive, or consumer-packaged-goods categories outside its operator experience.

OCV’s Co-Founder and Chairman Richard Ressler is also a co-founder of CIM Group, a Los Angeles-based real-asset and infrastructure manager. While the two firms share a founder, OCV operates as an independent venture capital entity focused on technology and healthcare, and no formal co-investment vehicle or shared balance sheet has been disclosed between them. The CIM Group connection does provide OCV with real-estate operating expertise that can benefit portfolio companies like Figure 8 (Museum of Ice Cream).

The firm’s principals generated their wealth primarily through operating roles, most notably building J2 Global from a startup into a publicly traded company (NASDAQ:JCOM). Hemi Zucker served as CEO, and Richard Ressler co-founded the business. Their capital is proprietary, earned from founding and scaling a venture-backed company to a successful IPO, rather than sourced from a single-family fortune.

OCV operates as a direct investor and frequently participates in syndicated rounds alongside other venture firms. The firm was a participant in Rad AI’s Series C led by Khosla Ventures, demonstrating a willingness to co-invest with large institutional VCs without demanding a lead role. The firm has not disclosed a dedicated co-investment program for limited partners.